A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Plain-language summary
This trial is testing chidamide (an oral HDAC inhibitor) for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Golidocitinib (DRUG): 150 mg, orally, once daily, with or without food, in a 21-day cycle | Chidamide (DRUG): 30 mg, orally, twice a week, with an interval of no less than 3 days in a 21-day cycle | Gemcitabine (DRUG): 1000 mg/m2, intravenous infusion, administered on Day 1, Day 8 and Day 15 of a 28-day cycle
Golidocitinib, Chidamide, Gemcitabine
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details